Drugs that contain Leuprolide Acetate
1. Drug name - ELIGARD KIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8470359 | TOLMAR THERAP | Sustained release polymer |
Oct, 2023
(1 year, 17 days from now) | |
| CN100536922C | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 6 days ago) | |
| CN1474685A | TOLMAR THERAP | Lupron Polymer Release Preparation With Improved Efficacy |
Sep, 2021
(1 year, 6 days ago) | |
| CN101669900B | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 6 days ago) | |
| CN101669900A | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 6 days ago) | |
| EP2158900B1 | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Feb, 2019
(3 years ago) | |
| EP2158900A1 | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Feb, 2019
(3 years ago) | |
| EP1126822B1 | TOLMAR THERAP | Controlled Release Liquid Delivery Compositions With Low Initial Drug Burst |
Oct, 2019
(2 years ago) | |
| EP1126822A1 | TOLMAR THERAP | Controlled Release Liquid Delivery Compositions With Low Initial Drug Burst |
Oct, 2019
(2 years ago) | |
| EP1322286B1 | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
| EP1322286B3 | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
| EP1586309B1 | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
| EP1322286A2 | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
| EP1586309A1 | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
| EP1586309B3 | TOLMAR THERAP | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
Treatment: NA
Dosage: POWDER;SUBCUTANEOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 22.5MG | POWDER;SUBCUTANEOUS | Prescription |
2. Drug name - FENSOLVI KIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8470359 | TOLMAR | Sustained release polymer |
Oct, 2023
(1 year, 17 days from now) | |
| CN100536922C | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 6 days ago) | |
| CN1474685A | TOLMAR | Lupron Polymer Release Preparation With Improved Efficacy |
Sep, 2021
(1 year, 6 days ago) | |
| CN101669900B | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 6 days ago) | |
| CN101669900A | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 6 days ago) | |
| EP2158900B1 | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Feb, 2019
(3 years ago) | |
| EP2158900A1 | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Feb, 2019
(3 years ago) | |
| EP1126822B1 | TOLMAR | Controlled Release Liquid Delivery Compositions With Low Initial Drug Burst |
Oct, 2019
(2 years ago) | |
| EP1126822A1 | TOLMAR | Controlled Release Liquid Delivery Compositions With Low Initial Drug Burst |
Oct, 2019
(2 years ago) | |
| EP1322286B1 | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
| EP1322286B3 | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
| EP1586309B1 | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
| EP1322286A2 | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
| EP1586309A1 | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
| EP1586309B3 | TOLMAR | Polymeric Delivery Formulations Of Leuprolide With Improved Efficacy |
Sep, 2021
(1 year, 7 days ago) | |
Treatment: NA
Dosage: POWDER;SUBCUTANEOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 45MG | POWDER;SUBCUTANEOUS | Prescription |
3. Drug name - LUPRON DEPOT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(8 years from now) | |
Treatment: Palliative treatment of prostate cancer
Dosage: INJECTABLE;INJECTION
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 22.5MG/VIAL | INJECTABLE;INJECTION | Prescription |
| 30MG/VIAL | INJECTABLE;INJECTION | Prescription |
| 45MG/VIAL | INJECTABLE;INJECTION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.